Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX), a global innovator in drug-delivery platforms, has released the results of its annual meeting, which was held June 28, 2021. According to the announcement, the meeting began at 1 p.m. PT with 2,735,413 company shares represented either in person or by proxy; that number constituted 53.6% of the company’s issued share capital as of May 3, 2021. There were several matters voted upon during the meeting, including the election of Chris Bunka, John Docherty, Nicholas Baxter, Ted McKechnie and Albert Reese Jr. as directors, with the percent approving the elections ranging from 82.1% to 97.6%. In addition, more than 99% of those in attendance voted to appoint Davidson & Company LLP as auditors. More than 68% voted to approve an amendment to the company’s equity incentive plan for the issuance of an additional 249,143 common shares, and almost 86% voted to ratify the lawful actions of the directors for the past year.
To view the full press release, visit https://ibn.fm/hu2P2
About Lexaria Bioscience Corp.
Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-virals, cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information about the company, please visit www.LexariaScience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
